[1. van Dongen JJM, Orfao A, on behalf of the EuroFlow Consortium. EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia. Sep 2012; 26(9): 1899-907. DOI: 10.1038/leu.2012.12110.1038/leu.2012.121]Search in Google Scholar
[2. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. Jan 12, 2012; 119(2): 521-9. DOI: 10.1182/blood-2011-09-37996610.1182/blood-2011-09-379966]Search in Google Scholar
[3. Gianfelici V. Activation of the NOTCH1 pathway in chronic lymphocytic leukemia. Haematologica March 2012; 97:328-30. DOI: 10.3324/haematol.2012.06172110.3324/haematol.2012.061721]Search in Google Scholar
[4. www.nccn.org]Search in Google Scholar
[5. Alcalay D, Deleplanque P, Maubras MA, Guilhot F.Therapeutic leukapheresis in a leukostasis syndrome complicating chronic lymphoid leukemia. Ann Med Interne (Paris). 1988;139 Suppl 1:53-4.]Search in Google Scholar
[6. de Fijter CW, Schuur J, Potter van Loon BJ, Kingma WP, Schweitzer MJ. Acute cardiorespiratory failure as presenting symptom of chronic lymphocytic leukemia. Neth J Med. 1996 Jul;49(1):33-7. DOI: 10.1016/0300-2977(96)00008-310.1016/0300-2977(96)00008-3]Search in Google Scholar
[7. Durzyński T, Konopka L, Traczyk Z. Leukostasis syndrome in a case of chronic lymphocytic leukemia. Pol Merkur Lekarski. 1999 Jan;6(31):30-1.]Search in Google Scholar
[8. Beaubien ER, Wilson TW, Satkunam N. Sudden death in a patient with chronic lymphocytic leukemia. CMAJ. 1998 Nov 3;159(9):1123-5.]Search in Google Scholar
[9. Cukierman T, Gatt ME, Libster D, Goldschmidt N, Matzner Y. Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk Lymphoma. 2002 Sep;43(9):1865-8. DOI: 10.1080/104281902100000636710.1080/104281902100000636712685846]Search in Google Scholar
[10. Bumbea H, Vladareanu AM, Vintilescu A, Radesi S, Ciufu C, Onisai M, et al. The lymphocyte immunophenotypical pattern in chronic lymphocytic leukemia associated with hepatitis viral infections. J Med Life. 2011 Aug 15;4(3):256-63.]Search in Google Scholar
[11. Gradowski JF, Sargent RL, Craig FE, Cieply K, Fuhrer K, Sherer C, Swerdlow SH. Chronic lymphocytic leukemia/ small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression. Am J Clin Pathol. 2012 Jul;138(1):132-9. DOI: 10.1309/ AJCPIVKZRMPF93ET10.1309/AJCPIVKZRMPF93ET370054022706868]Search in Google Scholar
[12. Swerdlow SH, Campo E, Seto M, et al. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of Haematopoietic and LymphoidTissues. Lyon, France: IARC; 2008. p. 229-2323.]Search in Google Scholar
[13. Gao J, Peterson L, Nelson B, et al. Immunophenotypic variations in mantle cell lymphoma. Am JClin Pathol. 2009; 132:699-706. DOI: 10.1309/AJCPV8LN5ENMZOVY10.1309/AJCPV8LN5ENMZOVY19846810]Search in Google Scholar
[14. O’Malley DP, Vance GH, Orazi A. Chronic lymphocytic leukemia/small lymphocytic lymphoma with trisomy 12 and focal cyclin D1 expression: a potential diagnostic pitfall. Arch Pathol LabMed. 2005; 129:92-5.10.5858/2005-129-92-CLSLLW15628916]Search in Google Scholar
[15. Abboudi Z, Patel K, Naresh KN. Cyclin D1 expression in typical chronic lymphocytic leukaemia.Eur J Haematol. 2009; 83:203-7. DOI: 10.1111/j.1600-0609.2009.01276.x10.1111/j.1600-0609.2009.01276.x19467018]Search in Google Scholar
[16. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111:3941-67. DOI: 10.1182/blood-2007-11-12053510.1182/blood-2007-11-12053518198345]Search in Google Scholar
[17. Ho AK, Hill S, Preobrazhensky SN, Miller ME, Chen Z, Bahler DW. Small B-cell neoplasms with typical mantle cell lymphoma immunophenotypes often include chronic lymphocytic leukemias. Am J Clin Pathol. 2009 Jan;131(1):27-32. DOI: 10.1309/AJCPPAG4VR4IPGHZ10.1309/AJCPPAG4VR4IPGHZ]Search in Google Scholar
[18. Grigore GE, Ivanov IC, Zlei M, Dăscălescu A, Popescu R, Petreuș T, et al. Specific Associations Between Clinical Signs, Immune Cells, Disease Genetic Background and Burden in a Group of Patients with B-Cell Chronic Lymphocytic Leukemia. Rev Romana Med Lab. 2014;22(1):79-92. DOI: 10.2478/rrlm 2014-0004]Search in Google Scholar
[19. te Raa GD, van Oers MH, Kater AP; HOVON CLL working party. Monoclonal B-cell lymphocytosis: recommendations from the Dutch Working Group on CLL for daily practice. Neth J Med. 2012 Jun;70(5):236-41.]Search in Google Scholar
[20. Sandes AF, de Lourdes Chauffaille M, Oliveira CR, Maekawa Y, Tamashiro N, Takao TT, et al. CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry. Cytometry B Clin Cytom. 2014 Mar;86(2):98-105. DOI: 10.1002/cyto.b.2112810.1002/cytob.21128]Search in Google Scholar
[21. Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012 Jan;137(1):93-100. DOI: 10.1309/ AJCP59UORCYZEVQO10.1309/AJCP59UORCYZEVQO]Search in Google Scholar
[22. El Desoukey NA, Afify RA, Amin DG, Mohammed RF. CD200 expression in B-cell chronic lymphoproliferative disorders. J Investig Med. 2012 Jan;60(1):56-61. DOI: 10.231/JIM.0b013e31823908f910.2310/JIM.0b013e31823908f9]Search in Google Scholar
[23. Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009 Sep;33(9):1212-6. DOI: 10.1016/j.leukres.]Search in Google Scholar
[2009.01.017]Search in Google Scholar
[24. Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. Jun 2014; 99(6):965-72. DOI: 10.3324/haematol.2013.09610710.3324/haematol.2013.096107]Search in Google Scholar
[25. Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, Gabrielli S, et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica. 2012 Mar;97(3):437-41. DOI: 10.3324/haematol.2011.06012910.3324/haematol.2011.060129]Search in Google Scholar
[26. Sportoletti P, Baldoni S, Del Papa B, Aureli P, Dorillo E, Ruggeri L, et al. A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia. Leukemia. 2014 Feb;28(2):436-9. DOI: 10.1038/leu.2013.28910.1038/leu.2013.289]Search in Google Scholar
[27. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, et al.Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014 May 22;123(21):3247-54. DOI: 10.1182/blood-2014-01-54615010.1182/blood-2014-01-546150]Search in Google Scholar
[28. Strati P, Keating MJ, O’Brien SM, Ferrajoli A, Burger J, Faderl S et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. Aug 2014; 99(8):1350-5. DOI: 10.3324/ haematol.2014.10466110.3324/haematol.2014.104661]Search in Google Scholar
[29. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2; 376(9747):1164-74. DOI: 10.1016/S0140-6736(10)61381-510.1016/S0140-6736(10)61381-5]Search in Google Scholar
[30. Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4079-88. DOI: 10.1200/JCO.2005.12.05110.1200/JCO.2005.12.05115767648]Search in Google Scholar
[31. Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15;112(4):975-80. DOI: 10.1182/ blood-2008-02-14058210.1182/blood-2008-02-140582395249818411418]Search in Google Scholar
[32. Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014 Jan;28(1):108-17. DOI: 10.1038/leu.2013.26310.1038/leu.2013.26324113472]Search in Google Scholar
[33. Tosello V, Ferrando AA. The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol. Jun 2013; 4(3): 199-210. DOI: 10.1177/2040620712471368 10.1177/2040620712471368366644523730497]Search in Google Scholar